Regarding Techcyte and Biobase Partnership on LinkedIn
recent articles
SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets,...
From LinkedIn regarding Techcyte and Biobase partnership Sam Seymour, CPO and Co-Founder at Biobase: I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology's adoption...
OREM, UT, UNITED STATES, May 4, 2026 /EINPresswire.com/ -- Techcyte is pleased to announce that a validation study conducted by the Contra Costa County Public Health Laboratory (CCPHL) evaluating its AI-assisted ova and parasite (O&P)...
From the Proscia blog: Going digital is a huge feat, and something well worth celebrating. But the labs seeing the biggest returns chose a platform that keeps compounding value long after go-live, scaling across departments and teams without...
Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly...
From the Proscia blog: We’ve long said that the next major therapeutic breakthrough may lie in pathology data that already exists. At this year’s AACR Annual Meeting, it became clear the biopharma community is arriving at the same...
